<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="83184">
  <stage>Registered</stage>
  <submitdate>17/08/2005</submitdate>
  <approvaldate>17/08/2005</approvaldate>
  <actrnumber>ACTRN12608000470392</actrnumber>
  <trial_identification>
    <studytitle>A placebo controlled randomized trial of long-term antibiotics to prevent recurrent urinary tract infection in children</studytitle>
    <scientifictitle>A trial of long term cotrimoxazole compared to placebo to prevent recurrent urinary tract infection in children</scientifictitle>
    <utrn />
    <trialacronym>PRIVENT</trialacronym>
    <secondaryid>nil known
</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Urinary tract infection</healthcondition>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Kidney disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Low dose continuous, daily, cotrimoxazole for 12 months.  Oral route. Dose is calculated by volume according to body weight; 2mg/kg of Trimethoprim and 10mg/kg sulphamethoxazole.  This works out to be 0.25mL/kg of 200-40mg/5mL suspension.  Dose is increased every 3 months to the nearest 0.5mL as the child grows.  Children take medication once per day for 12 months.</interventions>
    <comparator>Placebo, taste and colour matched to active.  Oral route, once daily for 12 months.  Placebo is liquid, colour and taste matched to active treatment.  Made specifically for this trial by accredited laboratory. 0.25mL/kg as single daily dose, increased every 3 months to nearest 0.5mL.  This is identical to the volume given in the active treatment arm.</comparator>
    <control>Placebo</control>
    <interventioncode>Prevention</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Repeat symptomatic microbiologically proven urinary tract infection.  Measured by direct questioning of parents at 3, 6, 9 and 12 month clinic reviews.  Any parent stating yes to a urinary tract infection is asked for consent to contact primary care giver and obtain details.  Trial coordinators at each centre contact health providers and obtain a copy of microbioligucal report on the urine culture.</outcome>
      <timepoint>3, 6, 9 and 12 month followup</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Febrile urinary tract infection.  Measured by direct questioning of parent at 3,6,9 and 12 month time points and verified with appropriate health care providers record of microbiological result</outcome>
      <timepoint>Asked at 3, 6, 9 and 12 months. Covers the period 0-12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Hospitalisation.  Measured by direct questioning of parent at 3,6,9 and 12 month time points</outcome>
      <timepoint>Asked at 3, 6, 9 and 12 months, covers the period 0-12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Adverse drug reactions. Measured by direct questioning of parent at 3,6,9 and 12 month time points.  Questioned about occurrences of; diarrhoea, nausea, vomitting, rash, thrush, jaundice, anaphylaxis, haematoligic abnormalities</outcome>
      <timepoint>0-12 months, asked at 3, 6, 9 and 12 month reviews</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Antibiotic administration for other infectious disease.  Measured by direct questioning of parents at 3, 6, 9 and 12 month clinic reviews</outcome>
      <timepoint>0 -12 months, questioned at 3, 6, 9 and 12 month clinic review</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Abnorrmalities on dimercaptosuccinic acid scan (DMSA).  Children with abnormal initial DMSA scans are requested to undergo a repeat DMSA at 12 months.  All DMSA scans are centrally re-reported by one Senior Staff Specialist in nuclear medicine at The Children's Hospital at Westmead (CHW).  DMSA scans at 12 months are compared to initial scans and the single CHW reviewer codes the scans as to whether they are ; unchanged, partial improvement, complete improvement and no change.</outcome>
      <timepoint>Baseline, 12 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Children &lt;18 years, symptomatic microbiologically proven urinary tract infection</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>Days</inclusiveminagetype>
    <inclusivemaxage>18</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Asymptomatic urinary tract infection, Non-recurrent urinary tract infection in children &gt; 5 years, Bag urine sample, growth below threshold, not pure growth, predisposing causes; indwelling catheter, nosocomial infection, urological/nephrological disease (renal disese, pelviureteric obstruction, vesicoureteral obstruction, posterior urethral valves, renal tract malformations, renal calculi), neurological problems (spina bifida, spina cord injuries, neurogenic bladder, cerebral palsy) Glucose 6 phosphate dehydrogenase deficiency, sulphur allergy, non-resident of Australia</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Central randomisation by phone</concealment>
    <sequence>Computer generated randomisation by National Health and Medical Research Council (NHMRC) trial centre, Stratified by centre, referral course, frequency of prior UTIs, presen or absence of reflux, age and gender by the method of minimisation</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures>Taste and colour matched placebo. run-in period of active treament for 2 weeks.  Compliance assesed prior to randomisation.  Compliance measured by direct questioning and measured by amount of medication remaining in bottle at each 3 monthly review</designfeatures>
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>1/12/1998</anticipatedstartdate>
    <actualstartdate>2/11/1998</actualstartdate>
    <anticipatedenddate />
    <actualenddate>29/03/2007</actualenddate>
    <samplesize>780</samplesize>
    <actualsamplesize>576</actualsamplesize>
    <recruitmentstatus />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <postcode>1860</postcode>
    <postcode>2037</postcode>
    <postcode>2041</postcode>
    <postcode>2037</postcode>
    <postcode>2045</postcode>
    <postcode>2037</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>The Childrens Hospital at Westmead</primarysponsorname>
    <primarysponsoraddress>Locked bag 4001, Westmead, NSW 2145</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>National Health and Medical Research Council (NHMRC) of Australia</fundingname>
      <fundingaddress>GPO Box 1421, Canberra, ACT 2601</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Financial Markets Foundation of Australia</fundingname>
      <fundingaddress>GPO Box 3655 Sydney NSW 1044</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Other</fundingtype>
      <fundingname>JT Honan, Manildra Holdings</fundingname>
      <fundingaddress>Private Donation, Manildra Holdings Level 12, 72 Castlereagh Street,  Sydney NSW, 2000</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>University</sponsortype>
      <sponsorname>University of Sydney</sponsorname>
      <sponsoraddress>Camperdown, NSW 2006</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>University</othercollaboratortype>
      <othercollaboratorname>Australian National University Medical School</othercollaboratorname>
      <othercollaboratoraddress>Frank Fenner Building 42, The Australian National University, Canberra, ACT 0200</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>University</othercollaboratortype>
      <othercollaboratorname>University of Queensland</othercollaboratorname>
      <othercollaboratoraddress>Level 3 Foundation Building, Herston Road, Brisbane, Queensland 4029</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Hospital</othercollaboratortype>
      <othercollaboratorname>Royal Childrens Hospital</othercollaboratorname>
      <othercollaboratoraddress>50 Flemington Road, Parkville, Melbourne, Victoria 3052</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a multi-centre, blinded placebo-controlled randomised trial of long-term antibiotics in children.  Patients will be randomly allocated to either low dose cotrimoxazole or placebo and followed for 12 months. Randomisation will be performed centrally by the NHMRC Clinical Trials Centre with dynamic balancing of important confounders and stratified by vesicoureteric reflux.  Treatment allocation will be concealed. A total of 780 participants will be drawn from children routinely given long-term antibiotics, either because of their age (infants), what is thought to be a predisposing abnormality (vesicoureteric reflux), or because of recurrent infections.  Children will be monitored at 3, 6, 9 and 12 month clinics.  The primary outcome is repeat symptomatic microbiologically proven urinary tract infection</summary>
    <trialwebsite>http://www.kidney-research.org/privent.html</trialwebsite>
    <publication>N Engl J Med 2009;361:1748-59.</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Royal Alexandra Hospital for Children, The New Childrens Hospital</ethicname>
      <ethicaddress>Locked Bag 4001, Wetmead NSW 2145</ethicaddress>
      <ethicapprovaldate>20/12/1996</ethicapprovaldate>
      <hrec>96081, renewed 2002/051</hrec>
      <ethicsubmitdate>5/12/1996</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>The University of Sydney Human research Ethics committee</ethicname>
      <ethicaddress>Main Quadrangle, University of Sydney, Camperdown, NSW 2006</ethicaddress>
      <ethicapprovaldate>4/02/2002</ethicapprovaldate>
      <hrec>01/09/26</hrec>
      <ethicsubmitdate>9/09/2001</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Wentworth Area Health Service Ethics Committee</ethicname>
      <ethicaddress>Court Buliding PO Box 63 Penrith NSW 2751</ethicaddress>
      <ethicapprovaldate>13/04/2004</ethicapprovaldate>
      <hrec>03/016</hrec>
      <ethicsubmitdate>31/03/2004</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal CHildrens Hospital, Melbourne Ethics in Human Research Committee</ethicname>
      <ethicaddress>50 Flemington Road Parkville Victoria 3052</ethicaddress>
      <ethicapprovaldate>5/03/2002</ethicapprovaldate>
      <hrec>22007A, 22007P</hrec>
      <ethicsubmitdate>1/02/2002</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Childrens Hospital and Health Service District Ethics Committee</ethicname>
      <ethicaddress>RCH Foundation Building, Royal Childrens Hospital, Herston Road, Brisbane, Queensland 4029</ethicaddress>
      <ethicapprovaldate>20/05/2005</ethicapprovaldate>
      <hrec>6/10/05</hrec>
      <ethicsubmitdate>1/04/2005</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>ACT Health Human Research Ethics Committee</ethicname>
      <ethicaddress>GPO Box 825 Canberra ACT</ethicaddress>
      <ethicapprovaldate>13/03/2000</ethicapprovaldate>
      <hrec>ETH.2/00.54 refers</hrec>
      <ethicsubmitdate>1/02/2000</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Professor Jonathan Craig</name>
      <address>The Childrens Hospital at Westmead, Locked Bag 4001, Westmead, NSW 2145</address>
      <phone>0298453431</phone>
      <fax>0298451491</fax>
      <email>jonathan.craig@sydney.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Professor Jonathan Craig</name>
      <address>The Childrens Hospital at Westmead, Locked Bag 4001, Westmead, NSW 2145</address>
      <phone>0298453431</phone>
      <fax>0298451491</fax>
      <email>jonathan.craig@sydney.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Gabrielle Williams</name>
      <address>The Childrens Hospital at Westmead, Locked Bag 4001, Westmead, NSW 2145</address>
      <phone>0298451492</phone>
      <fax>0298451491</fax>
      <email>gabriew4@chw.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Jonathan Craig</name>
      <address>The Childrens Hospital at Westmead, Locked Bag 4001, Westmead, NSW 2145</address>
      <phone>0298451492</phone>
      <fax />
      <email>jonathan.craig@sydney.edu.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>